sorafenib has been researched along with Bile Duct Cancer in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Fey, D; Malik, IA; Rajput, M; Salehzadeh, N; von Arnim, CAF; Werner, R; Wilting, J | 1 |
| Christ, B; Koch, M; Leskova, M; Lieshout, R; Lissek, SM; Nickel, S; Pampaloni, F; van der Laan, LJW; Verstegen, MMA | 1 |
| Balcar, L; Finkelmeier, F; Himmelsbach, V; Mahyera, A; Mozayani, B; Pinter, M; Pomej, K; Scheiner, B; Shmanko, K; Trauner, M; Vogel, A; Weinmann, A; Welland, S | 1 |
| Ye, B; Zhang, J; Zheng, Y | 1 |
| Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T; Tanaka, T | 1 |
| Kitazawa, M; Kobayashi, A; Matsumura, T; Miyagawa, SI; Motoyama, H; Notake, T; Shimizu, A; Takeoka, M; Yokoi, K; Yokoyama, T | 1 |
| Al-Abdulla, R; Alonso-Peña, M; Andersen, JB; Asensio, M; Avila, MA; Banales, JM; Briz, O; Del Carmen, S; Lozano, E; Macias, RIR; Marin, JJG; Martinez-Chantar, ML; Monte, MJ; Munoz-Garrido, P; O'Rourke, CJ; Sanchez-Vicente, L; Satriano, L | 1 |
| Banales, JM; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RI; Marin, JJ; Vaquero, J | 1 |
| Chung, CW; Jeong, YI; Kang, DH; Kim, CH; Kim, DH; Kwak, TW; Lee, HM | 1 |
| Dokduang, H; Juntana, S; Khuntikeo, N; Loilome, W; Namwat, N; Riggins, GJ; Techasen, A; Yongvanit, P | 1 |
| Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH | 1 |
| Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB | 1 |
| Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S | 1 |
| Boakye, J; Chaiteerakij, R; Chen, G; Ding, X; Huang, S; Li, Y; Moser, CD; Ndzengue, A; Roberts, LR; Shaleh, H; Sinicrope, FA; Smith, CD; Thomas, MB; Zhou, Y; Zou, X | 1 |
| Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z | 1 |
| Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T | 1 |
| Foreman, B; Hicks, MD; LaRocca, RV; Mull, L | 1 |
| Barreiros, AP; Galle, PR; Krupp, M; Maass, T; Strand, S; Teufel, A; Thieringer, F; Wang, C; Wörns, MA | 1 |
| Blechacz, BR; Bronk, SF; Gores, GJ; Sirica, AE; Smoot, RL; Werneburg, NW | 1 |
| Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S | 1 |
| Huang, FK; Shi, Z | 1 |
| Baba, N; Hyodo, I; Ishige, K; Matsuda, S; Nakanuma, Y; Onodera, M; Onuki, K; Shoda, J; Sugiyama, H; Takeuchi, K; Ueda, T; Yamamoto, M; Yamato, M | 1 |
| Faris, JE; Zhu, AX | 1 |
1 review(s) available for sorafenib and Bile Duct Cancer
| Article | Year |
|---|---|
Targeted therapy for biliary tract cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Gallbladder Neoplasms; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Panitumumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
5 trial(s) available for sorafenib and Bile Duct Cancer
| Article | Year |
|---|---|
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A | 2014 |
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemokine CXCL12; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2014 |
Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diarrhea; Drug Administration Schedule; Exanthema; Fatigue; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2017 |
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Gallbladder Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sorafenib | 2010 |
17 other study(ies) available for sorafenib and Bile Duct Cancer
| Article | Year |
|---|---|
Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Dasatinib; Hepatoblastoma; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; Sorafenib | 2022 |
Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Humans; Ki-67 Antigen; Organoids; Sorafenib | 2022 |
Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib | 2023 |
miR-138 mediates sorafenib-induced cell survival and is associated with poor prognosis in cholangiocarcinoma cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Cell Survival; Cholangiocarcinoma; Female; Humans; Male; MicroRNAs; Middle Aged; Prognosis; Sorafenib | 2020 |
Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Sorafenib; Survival Rate | 2020 |
Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Topics: Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2018 |
Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Disease Models, Animal; DNA Methylation; Down-Regulation; Drug Resistance; Genetic Therapy; Humans; Immunoblotting; Male; Octamer Transcription Factor-1; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Statistics, Nonparametric | 2019 |
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Cholangiocarcinoma; Female; Humans; In Vitro Techniques; Liver Neoplasms; Molecular Sequence Data; Niacinamide; Oocytes; Organic Cation Transporter 1; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sorafenib; Treatment Outcome; Xenopus laevis | 2013 |
Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Evaluation, Preclinical; Drug-Eluting Stents; Human Umbilical Vein Endothelial Cells; Humans; Male; Matrix Metalloproteinase 2; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Polyesters; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug Synergism; Drug Therapy, Combination; Humans; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Cells, Cultured | 2016 |
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays | 2016 |
Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
Topics: Adult; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Female; Humans; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome | 2007 |
A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biological Evolution; Cholangiocarcinoma; Computational Biology; Databases, Genetic; Extracellular Space; Humans; MAP Kinase Signaling System; Mice; Multigene Family; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyridines; Sorafenib; Systems Biology | 2009 |
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Topics: Animals; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Enzyme Activation; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Tyrosine | 2009 |
[Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Dose-Response Relationship, Drug; Down-Regulation; Humans; Lymphangiogenesis; Lymphatic Vessels; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Random Allocation; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3 | 2010 |
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Xenograft Model Antitumor Assays | 2011 |